AtriCure, Inc. (ATRC)
| Market Cap | 1.93B |
| Revenue (ttm) | 289.63M |
| Net Income (ttm) | 51.93M |
| Shares Out | 46.29M |
| EPS (ttm) | 1.09 |
| PE Ratio | 38.32 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 305,373 |
| Open | 42.08 |
| Previous Close | 43.08 |
| Day's Range | 40.74 - 42.75 |
| 52-Week Range | 38.64 - 89.18 |
| Beta | 1.10 |
| Analysts | Buy |
| Price Target | 82.28 (+97.0%) |
| Earnings Date | May 3, 2022 |
About ATRC
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for ATRC stock is "Buy." The 12-month stock price forecast is 82.28, which is an increase of 96.98% from the latest price.
News
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -22.22% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AtriCure Reports First Quarter 2022 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-oper...
AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-oper...
AtriCure to Announce First Quarter 2022 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-ope...
Wall Street Analysts Think AtriCure (ATRC) Could Surge 52%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the positiv...
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -15.38% and 0.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure Reports Fourth Quarter 2021 and Full Year 2021 Financial Results
MASON, Ohio,--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-ope...
AtriCure (ATRC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure Publishes Inaugural ESG Report
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-oper...
AtriCure to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-ope...
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-ope...
AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure (ATRC) Tops Q3 Earnings and Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of 739.39% and 2.19%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure Reports Third Quarter 2021 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 20...
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure to Participate in Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure to Announce Third Quarter 2021 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...
AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AtriCure Reports Second Quarter 2021 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2...
AtriCure to Participate at the Canaccord 41st Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...
AtriCure to Announce Second Quarter 2021 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...
AtriCure Names Two New Members to the Board of Directors
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. ...